Thus, there is a true medical need for new cost-effective and practical alternatives such as GIC-1001, an oral peripherally-acting, dual-action opioid agonist which releases active hydrogen sulfide (H2S) in-vivo. Aims To establish a preliminary clinical profile of GIC-1001, in light of Phase...